Leptin and leptin receptor expressions in prostate tumors may predict disease aggressiveness?
AUTOR(ES)
Osório, Clarice F., Souza, Diogo B. de, Gallo, Carla B. M., Costa, Waldemar S., Sampaio, Francisco J. B.
FONTE
Acta Cir. Bras.
DATA DE PUBLICAÇÃO
2014
RESUMO
PURPOSE: The aim of this study was to evaluate the expression of leptin and its receptor in histological sections of prostate tumors, and their association with prognostic factors. METHODS: A total of 532 surgical specimens from prostate cancer were studied. After histopathological diagnosis, the samples were included in tissue microarrays containing cores from tumor and non-tumor (benign prostatic hyperplasia) areas. These were immunostained with anti-leptin and anti-leptin-receptor antibodies. Objective and subjective analyses were performed. Student's-t-test and ANOVA were used to compare mean values, and linear regression was used to evaluate the correlation between histological results and prognostic indicators. RESULTS: Leptin receptor expression was reduced in tumors with a positive surgical margin, urethral margin involvement, and seminal vesicles invasion. Further, there was a negative correlation between the expression of leptin receptor in tumor areas and the sum of prognostic factors, suggesting that leptin receptor may predict the aggressiveness of disease. CONCLUSION: Our findings suggest that leptin receptor expression is a potential prognostic factor for PCa. Further investigation is needed to support the use of leptin receptor as a novel biomarker, although leptin itself does not seem to predict the aggressiveness of prostate cancer.
Documentos Relacionados
- Leucocyte count may predict heart disease in women
- Cytokine genetic polymorphisms and prostate cancer aggressiveness
- Leptin and leptin receptor mRNA and protein expression in the murine fetus and placenta
- Mapping leptin-interacting sites in recombinant leptin-binding domain (LBD) subcloned from chicken leptin receptor
- Study of testosterone as a predictor of tumor aggressiveness in patients with prostate cancer